Melperone hydrochloride5-HT2A/D2 receptor antagonist; neuroleptic CAS# 1622-79-3 |
- FK 3311
Catalog No.:BCC1576
CAS No.:116686-15-8
- Iguratimod
Catalog No.:BCC1641
CAS No.:123663-49-0
- Celecoxib
Catalog No.:BCC1099
CAS No.:169590-42-5
- Etoricoxib
Catalog No.:BCC1565
CAS No.:202409-33-4
- Ibuprofen Lysine
Catalog No.:BCC2547
CAS No.:57469-77-9
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1622-79-3 | SDF | Download SDF |
PubChem ID | 9926325 | Appearance | Powder |
Formula | C16H23ClFNO | M.Wt | 299.81 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in water and to 100 mM in DMSO | ||
Chemical Name | 1-(4-fluorophenyl)-4-(4-methylpiperidin-1-yl)butan-1-one;hydrochloride | ||
SMILES | CC1CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F.Cl | ||
Standard InChIKey | MQHYXXIJLKFQGY-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C16H22FNO.ClH/c1-13-8-11-18(12-9-13)10-2-3-16(19)14-4-6-15(17)7-5-14;/h4-7,13H,2-3,8-12H2,1H3;1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Atypical neuroleptic; 5-HT2A/D2 receptor antagonist (Ki values are 120 and 180 nM respectively). Causes an increase in dopamine levels in the medial prefrontal cortex (mPFC) and nucleus accumbens and an increase in ACh in the mPFC. Also binds adrenergic α1 and α2 receptors (Ki values are 180 and 150 nM respectively). |
Melperone hydrochloride Dilution Calculator
Melperone hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.3354 mL | 16.6772 mL | 33.3545 mL | 66.7089 mL | 83.3861 mL |
5 mM | 0.6671 mL | 3.3354 mL | 6.6709 mL | 13.3418 mL | 16.6772 mL |
10 mM | 0.3335 mL | 1.6677 mL | 3.3354 mL | 6.6709 mL | 8.3386 mL |
50 mM | 0.0667 mL | 0.3335 mL | 0.6671 mL | 1.3342 mL | 1.6677 mL |
100 mM | 0.0334 mL | 0.1668 mL | 0.3335 mL | 0.6671 mL | 0.8339 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Flunitrazepam
Catalog No.:BCC6107
CAS No.:1622-62-4
- RWJ 50271
Catalog No.:BCC7894
CAS No.:162112-37-0
- SynaptoRedTM C2
Catalog No.:BCC8012
CAS No.:162112-35-8
- 4',4'''-Di-O-methylisochamaejasmin
Catalog No.:BCN6849
CAS No.:1620921-68-7
- Dimesna
Catalog No.:BCC1095
CAS No.:16208-51-8
- Myriceric acid C
Catalog No.:BCN1719
CAS No.:162059-94-1
- SC 58125
Catalog No.:BCC5948
CAS No.:162054-19-5
- L-371,257
Catalog No.:BCC7353
CAS No.:162042-44-6
- UNC0379
Catalog No.:BCC8055
CAS No.:1620401-82-2
- Rofecoxib
Catalog No.:BCC4437
CAS No.:162011-90-7
- Bromosporine
Catalog No.:BCC2226
CAS No.:1619994-69-2
- GSK2801
Catalog No.:BCC6498
CAS No.:1619994-68-1
- 5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine 2',3'-diacetate
Catalog No.:BCN1544
CAS No.:162204-20-8
- Dorsmanin A
Catalog No.:BCN4088
CAS No.:162229-27-8
- CI 1020
Catalog No.:BCC7523
CAS No.:162256-50-0
- 7,3'-Dihydroxy-4'-methoxyflavan
Catalog No.:BCN4698
CAS No.:162290-05-3
- Remodelin
Catalog No.:BCC5571
CAS No.:1622921-15-6
- Baccatin X
Catalog No.:BCN7214
CAS No.:1623069-76-0
- Oplopanaxoside C
Catalog No.:BCC8226
CAS No.:162341-29-9
- Baccatin VIII
Catalog No.:BCN7212
CAS No.:1623410-10-5
- Baccatin IX
Catalog No.:BCN7213
CAS No.:1623410-12-7
- Hydramicromelin D
Catalog No.:BCN7548
CAS No.:1623437-86-4
- 1-Octanone,1-[4-[2-(acetyloxy)ethyl]phenyl]
Catalog No.:BCN2251
CAS No.:162358-03-4
- Benzeneethanol, 4-octyl-, 1-acetate
Catalog No.:BCN2252
CAS No.:162358-04-5
Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism.[Pubmed:12445705]
Brain Res. 2002 Nov 29;956(2):349-57.
Preferential increases in both cortical dopamine (DA) and acetylcholine (ACh) release have been proposed to distinguish the atypical antipsychotic drugs (APDs) clozapine, olanzapine, risperidone and ziprasidone from typical APDs such as haloperidol. Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade. However, WAY100635 does not attenuate clozapine-induced cortical ACh release. The present study determined whether quetiapine, iloperidone and melperone, 5-HT(2A)/D(2) antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to 5-HT(1A) agonism. Quetiapine (30 mg/kg), iloperidone (1-10 mg/kg), and melperone (3-10 mg/kg) increased DA and ACh release in the medial prefrontal cortex (mPFC). Iloperidone (10 mg/kg) and melperone (10 mg/kg), but not quetiapine (30 mg/kg), produced an equivalent or a smaller increase in DA release in the nucleus accumbens (NAC), respectively, compared to the mPFC, whereas none of them increased ACh release in the NAC. WAY100635 (0.2 mg/kg), which alone did not affect DA or ACh release, partially attenuated quetiapine (30 mg/kg)-, iloperidone (10 mg/kg)- and melperone (10 mg/kg)-induced DA release in the mPFC. WAY100635 also partially attenuated quetiapine (30 mg/kg)-induced ACh release in the mPFC, but not that induced by iloperidone (10 mg/kg) or melperone (10 mg/kg). These results indicate that quetiapine, iloperidone and melperone preferentially increase DA release in the mPFC, compared to the NAC via a 5-HT(1A)-related mechanism. However, 5-HT(1A) agonism may be important only for quetiapine-induced ACh release.
Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors.[Pubmed:9015795]
Neuropsychopharmacology. 1997 Feb;16(2):93-110; discussion 111-35.
This review examines the possible receptor basis of the atypical action of those atypical antipsychotic drugs that elicit low levels of Parkinsonism. Such an examination requires consistent and accurate dissociation constants for the antipsychotic drugs at the relevant dopamine and serotonin receptors. It has long been known, however, that the dissociation constant of a given antipsychotic drug at the dopamine D2 receptor varies between laboratories. Although such variation depends on several factors, it has recently been recognized that the radioligand used to measure the competition between the antipsychotic drug and the radioligand is an important variable. The present review summarizes information on this radioligand dependence. In general, a radioligand of low solubility in the membrane (i.e., low tissue:buffer partition) results in a low value for the antipsychotic dissociation constant when the drug competes with the radioligand. Hence, by first obtaining the antipsychotic dissociation constants using different radioligands of different solubility in the membrane, one can then extrapolate the data to low or "zero" ligand solubility. The extrapolated value represents the radioligand-independent dissociation constant of the antipsychotic. These values are here given for dopamine D2 and D4 receptors, as well as for serotonin 5-HT2A receptors. These values, moreover, agree with the dissociation constant directly obtained with the radioactive antipsychotic itself. For example, clozapine revealed a radioligand-independent value of 1.6 nM at the dopamine D4 receptor, agreeing with the value directly measured with [3H]-clozapine at D4. However, because clozapine competes with endogenous dopamine, the in vivo concentration of clozapine (to occupy dopamine D4 receptors) can be derived to be about 13 nM, agreeing with the value of 12 to 20 nM in the plasma water or spinal fluid observed in treated patients. The atypical neuroleptics remoxipride, clozapine, perlapine, seroquel, and melperone had low affinity for the dopamine D2 receptor (radioligand-independent dissociation constants of 30 to 90 nM). Such low affinity makes these latter five drugs readily displaceable by high levels of endogenous dopamine in the caudate or putamen. Most typical neuroleptics have radioligand-independent values of 0.3 to 5 nM at dopamine D2 receptors, making them more resistant to displacement by endogenous dopamine. Finally, a relation was found between the neuroleptic doses for rat catalepsy and the D2:D4 ratio of the radioligand-independent K values for these two receptors. Thus, the atypical neuroleptics appear to fall into two groups, those that have a low affinity for dopamine D2 receptors and those that are selective for dopamine D4 receptors.